Neurodegenerative Drugs Industry Research Report 2025
Description
Summary
According to APO Research, the global Neurodegenerative Drugs market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Neurodegenerative Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Neurodegenerative Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Neurodegenerative Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Neurodegenerative Drugs include TEVA, Sanofi, Novartis, Luye Pharma, Livzon Pharmaceutical, Kanghong Pharmaceutical, Jingxin Pharmaceutical, Pfizer and Huahai Pharmaceutical, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Neurodegenerative Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neurodegenerative Drugs.
The report will help the Neurodegenerative Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
The Neurodegenerative Drugs market size, estimations, and forecasts are provided in terms of sales volume (Tons) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Neurodegenerative Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Neurodegenerative Drugs Segment by Company
TEVA
Sanofi
Novartis
Luye Pharma
Livzon Pharmaceutical
Kanghong Pharmaceutical
Jingxin Pharmaceutical
Pfizer
Huahai Pharmaceutical
Hisun Pharmaceutical
Haisco Pharmaceutical
GlaxoSmithKline
Ark Pharmaceutical
Dongcheng Biochemicals
BORA PHARMACEUTICALS
UCB
Merck Serono
Boehringer Ingelheim
Biogen Idec
Neurodegenerative Drugs Segment by Type
NMDA
SSRIs
Dopamine Inhibitors
Neurodegenerative Drugs Segment by Application
Parkinson’s Disease
Amyotrophic Lateral Sclerosis
Huntington Disease
Alzheimer’s Disease
Neurodegenerative Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neurodegenerative Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Neurodegenerative Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neurodegenerative Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Neurodegenerative Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Neurodegenerative Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Neurodegenerative Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
According to APO Research, the global Neurodegenerative Drugs market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Neurodegenerative Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Neurodegenerative Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Neurodegenerative Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Neurodegenerative Drugs include TEVA, Sanofi, Novartis, Luye Pharma, Livzon Pharmaceutical, Kanghong Pharmaceutical, Jingxin Pharmaceutical, Pfizer and Huahai Pharmaceutical, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Neurodegenerative Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neurodegenerative Drugs.
The report will help the Neurodegenerative Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
The Neurodegenerative Drugs market size, estimations, and forecasts are provided in terms of sales volume (Tons) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Neurodegenerative Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Neurodegenerative Drugs Segment by Company
TEVA
Sanofi
Novartis
Luye Pharma
Livzon Pharmaceutical
Kanghong Pharmaceutical
Jingxin Pharmaceutical
Pfizer
Huahai Pharmaceutical
Hisun Pharmaceutical
Haisco Pharmaceutical
GlaxoSmithKline
Ark Pharmaceutical
Dongcheng Biochemicals
BORA PHARMACEUTICALS
UCB
Merck Serono
Boehringer Ingelheim
Biogen Idec
Neurodegenerative Drugs Segment by Type
NMDA
SSRIs
Dopamine Inhibitors
Neurodegenerative Drugs Segment by Application
Parkinson’s Disease
Amyotrophic Lateral Sclerosis
Huntington Disease
Alzheimer’s Disease
Neurodegenerative Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neurodegenerative Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Neurodegenerative Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neurodegenerative Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Neurodegenerative Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Neurodegenerative Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Neurodegenerative Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
Table of Contents
134 Pages
- 1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
- 2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Neurodegenerative Drugs Market Size (2020-2031)
- 2.2.2 Global Neurodegenerative Drugs Sales (2020-2031)
- 2.2.3 Global Neurodegenerative Drugs Market Average Price (2020-2031)
- 2.3 Neurodegenerative Drugs by Type
- 2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
- 2.3.2 NMDA
- 2.3.3 SSRIs
- 2.3.4 Dopamine Inhibitors
- 2.4 Neurodegenerative Drugs by Application
- 2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
- 2.4.2 Parkinson’s Disease
- 2.4.3 Amyotrophic Lateral Sclerosis
- 2.4.4 Huntington Disease
- 2.4.5 Alzheimer’s Disease
- 3 Market Competitive Landscape by Manufacturers
- 3.1 Global Neurodegenerative Drugs Market Competitive Situation by Manufacturers (2020 Versus 2024)
- 3.2 Global Neurodegenerative Drugs Sales (Tons) of Manufacturers (2020-2025)
- 3.3 Global Neurodegenerative Drugs Revenue of Manufacturers (2020-2025)
- 3.4 Global Neurodegenerative Drugs Average Price by Manufacturers (2020-2025)
- 3.5 Global Neurodegenerative Drugs Industry Ranking, 2023 VS 2024 VS 2025
- 3.6 Global Manufacturers of Neurodegenerative Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Neurodegenerative Drugs, Product Type & Application
- 3.8 Global Manufacturers of Neurodegenerative Drugs, Established Date
- 3.9 Global Neurodegenerative Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
- 4 Manufacturers Profiled
- 4.1 TEVA
- 4.1.1 TEVA Company Information
- 4.1.2 TEVA Business Overview
- 4.1.3 TEVA Neurodegenerative Drugs Sales, Revenue and Gross Margin (2020-2025)
- 4.1.4 TEVA Neurodegenerative Drugs Product Portfolio
- 4.1.5 TEVA Recent Developments
- 4.2 Sanofi
- 4.2.1 Sanofi Company Information
- 4.2.2 Sanofi Business Overview
- 4.2.3 Sanofi Neurodegenerative Drugs Sales, Revenue and Gross Margin (2020-2025)
- 4.2.4 Sanofi Neurodegenerative Drugs Product Portfolio
- 4.2.5 Sanofi Recent Developments
- 4.3 Novartis
- 4.3.1 Novartis Company Information
- 4.3.2 Novartis Business Overview
- 4.3.3 Novartis Neurodegenerative Drugs Sales, Revenue and Gross Margin (2020-2025)
- 4.3.4 Novartis Neurodegenerative Drugs Product Portfolio
- 4.3.5 Novartis Recent Developments
- 4.4 Luye Pharma
- 4.4.1 Luye Pharma Company Information
- 4.4.2 Luye Pharma Business Overview
- 4.4.3 Luye Pharma Neurodegenerative Drugs Sales, Revenue and Gross Margin (2020-2025)
- 4.4.4 Luye Pharma Neurodegenerative Drugs Product Portfolio
- 4.4.5 Luye Pharma Recent Developments
- 4.5 Livzon Pharmaceutical
- 4.5.1 Livzon Pharmaceutical Company Information
- 4.5.2 Livzon Pharmaceutical Business Overview
- 4.5.3 Livzon Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2020-2025)
- 4.5.4 Livzon Pharmaceutical Neurodegenerative Drugs Product Portfolio
- 4.5.5 Livzon Pharmaceutical Recent Developments
- 4.6 Kanghong Pharmaceutical
- 4.6.1 Kanghong Pharmaceutical Company Information
- 4.6.2 Kanghong Pharmaceutical Business Overview
- 4.6.3 Kanghong Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2020-2025)
- 4.6.4 Kanghong Pharmaceutical Neurodegenerative Drugs Product Portfolio
- 4.6.5 Kanghong Pharmaceutical Recent Developments
- 4.7 Jingxin Pharmaceutical
- 4.7.1 Jingxin Pharmaceutical Company Information
- 4.7.2 Jingxin Pharmaceutical Business Overview
- 4.7.3 Jingxin Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2020-2025)
- 4.7.4 Jingxin Pharmaceutical Neurodegenerative Drugs Product Portfolio
- 4.7.5 Jingxin Pharmaceutical Recent Developments
- 4.8 Pfizer
- 4.8.1 Pfizer Company Information
- 4.8.2 Pfizer Business Overview
- 4.8.3 Pfizer Neurodegenerative Drugs Sales, Revenue and Gross Margin (2020-2025)
- 4.8.4 Pfizer Neurodegenerative Drugs Product Portfolio
- 4.8.5 Pfizer Recent Developments
- 4.9 Huahai Pharmaceutical
- 4.9.1 Huahai Pharmaceutical Company Information
- 4.9.2 Huahai Pharmaceutical Business Overview
- 4.9.3 Huahai Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2020-2025)
- 4.9.4 Huahai Pharmaceutical Neurodegenerative Drugs Product Portfolio
- 4.9.5 Huahai Pharmaceutical Recent Developments
- 4.10 Hisun Pharmaceutical
- 4.10.1 Hisun Pharmaceutical Company Information
- 4.10.2 Hisun Pharmaceutical Business Overview
- 4.10.3 Hisun Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2020-2025)
- 4.10.4 Hisun Pharmaceutical Neurodegenerative Drugs Product Portfolio
- 4.10.5 Hisun Pharmaceutical Recent Developments
- 4.11 Haisco Pharmaceutical
- 4.11.1 Haisco Pharmaceutical Company Information
- 4.11.2 Haisco Pharmaceutical Business Overview
- 4.11.3 Haisco Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2020-2025)
- 4.11.4 Haisco Pharmaceutical Neurodegenerative Drugs Product Portfolio
- 4.11.5 Haisco Pharmaceutical Recent Developments
- 4.12 GlaxoSmithKline
- 4.12.1 GlaxoSmithKline Company Information
- 4.12.2 GlaxoSmithKline Business Overview
- 4.12.3 GlaxoSmithKline Neurodegenerative Drugs Sales, Revenue and Gross Margin (2020-2025)
- 4.12.4 GlaxoSmithKline Neurodegenerative Drugs Product Portfolio
- 4.12.5 GlaxoSmithKline Recent Developments
- 4.13 Ark Pharmaceutical
- 4.13.1 Ark Pharmaceutical Company Information
- 4.13.2 Ark Pharmaceutical Business Overview
- 4.13.3 Ark Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2020-2025)
- 4.13.4 Ark Pharmaceutical Neurodegenerative Drugs Product Portfolio
- 4.13.5 Ark Pharmaceutical Recent Developments
- 4.14 Dongcheng Biochemicals
- 4.14.1 Dongcheng Biochemicals Company Information
- 4.14.2 Dongcheng Biochemicals Business Overview
- 4.14.3 Dongcheng Biochemicals Neurodegenerative Drugs Sales, Revenue and Gross Margin (2020-2025)
- 4.14.4 Dongcheng Biochemicals Neurodegenerative Drugs Product Portfolio
- 4.14.5 Dongcheng Biochemicals Recent Developments
- 4.15 BORA PHARMACEUTICALS
- 4.15.1 BORA PHARMACEUTICALS Company Information
- 4.15.2 BORA PHARMACEUTICALS Business Overview
- 4.15.3 BORA PHARMACEUTICALS Neurodegenerative Drugs Sales, Revenue and Gross Margin (2020-2025)
- 4.15.4 BORA PHARMACEUTICALS Neurodegenerative Drugs Product Portfolio
- 4.15.5 BORA PHARMACEUTICALS Recent Developments
- 4.16 UCB
- 4.16.1 UCB Company Information
- 4.16.2 UCB Business Overview
- 4.16.3 UCB Neurodegenerative Drugs Sales, Revenue and Gross Margin (2020-2025)
- 4.16.4 UCB Neurodegenerative Drugs Product Portfolio
- 4.16.5 UCB Recent Developments
- 4.17 Merck Serono
- 4.17.1 Merck Serono Company Information
- 4.17.2 Merck Serono Business Overview
- 4.17.3 Merck Serono Neurodegenerative Drugs Sales, Revenue and Gross Margin (2020-2025)
- 4.17.4 Merck Serono Neurodegenerative Drugs Product Portfolio
- 4.17.5 Merck Serono Recent Developments
- 4.18 Boehringer Ingelheim
- 4.18.1 Boehringer Ingelheim Company Information
- 4.18.2 Boehringer Ingelheim Business Overview
- 4.18.3 Boehringer Ingelheim Neurodegenerative Drugs Sales, Revenue and Gross Margin (2020-2025)
- 4.18.4 Boehringer Ingelheim Neurodegenerative Drugs Product Portfolio
- 4.18.5 Boehringer Ingelheim Recent Developments
- 4.19 Biogen Idec
- 4.19.1 Biogen Idec Company Information
- 4.19.2 Biogen Idec Business Overview
- 4.19.3 Biogen Idec Neurodegenerative Drugs Sales, Revenue and Gross Margin (2020-2025)
- 4.19.4 Biogen Idec Neurodegenerative Drugs Product Portfolio
- 4.19.5 Biogen Idec Recent Developments
- 5 Global Neurodegenerative Drugs Market Scenario by Region
- 5.1 Global Neurodegenerative Drugs Market Size by Region: 2020 VS 2024 VS 2031
- 5.2 Global Neurodegenerative Drugs Sales by Region: 2020-2031
- 5.2.1 Global Neurodegenerative Drugs Sales by Region: 2020-2025
- 5.2.2 Global Neurodegenerative Drugs Sales by Region: 2026-2031
- 5.3 Global Neurodegenerative Drugs Revenue by Region: 2020-2031
- 5.3.1 Global Neurodegenerative Drugs Revenue by Region: 2020-2025
- 5.3.2 Global Neurodegenerative Drugs Revenue by Region: 2026-2031
- 5.4 North America Neurodegenerative Drugs Market Facts & Figures by Country
- 5.4.1 North America Neurodegenerative Drugs Market Size by Country: 2020 VS 2024 VS 2031
- 5.4.2 North America Neurodegenerative Drugs Sales by Country (2020-2031)
- 5.4.3 North America Neurodegenerative Drugs Revenue by Country (2020-2031)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Neurodegenerative Drugs Market Facts & Figures by Country
- 5.5.1 Europe Neurodegenerative Drugs Market Size by Country: 2020 VS 2024 VS 2031
- 5.5.2 Europe Neurodegenerative Drugs Sales by Country (2020-2031)
- 5.5.3 Europe Neurodegenerative Drugs Revenue by Country (2020-2031)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Neurodegenerative Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Neurodegenerative Drugs Market Size by Country: 2020 VS 2024 VS 2031
- 5.6.2 Asia Pacific Neurodegenerative Drugs Sales by Country (2020-2031)
- 5.6.3 Asia Pacific Neurodegenerative Drugs Revenue by Country (2020-2031)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Neurodegenerative Drugs Market Facts & Figures by Country
- 5.7.1 South America Neurodegenerative Drugs Market Size by Country: 2020 VS 2024 VS 2031
- 5.7.2 South America Neurodegenerative Drugs Sales by Country (2020-2031)
- 5.7.3 South America Neurodegenerative Drugs Revenue by Country (2020-2031)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.7.7 Colombia
- 5.8 Middle East and Africa Neurodegenerative Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Neurodegenerative Drugs Market Size by Country: 2020 VS 2024 VS 2031
- 5.8.2 Middle East and Africa Neurodegenerative Drugs Sales by Country (2020-2031)
- 5.8.3 Middle East and Africa Neurodegenerative Drugs Revenue by Country (2020-2031)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
- 6 Segment by Type
- 6.1 Global Neurodegenerative Drugs Sales by Type (2020-2031)
- 6.1.1 Global Neurodegenerative Drugs Sales by Type (2020-2031) & (Tons)
- 6.1.2 Global Neurodegenerative Drugs Sales Market Share by Type (2020-2031)
- 6.2 Global Neurodegenerative Drugs Revenue by Type (2020-2031)
- 6.2.1 Global Neurodegenerative Drugs Sales by Type (2020-2031) & (US$ Million)
- 6.2.2 Global Neurodegenerative Drugs Revenue Market Share by Type (2020-2031)
- 6.3 Global Neurodegenerative Drugs Price by Type (2020-2031)
- 7 Segment by Application
- 7.1 Global Neurodegenerative Drugs Sales by Application (2020-2031)
- 7.1.1 Global Neurodegenerative Drugs Sales by Application (2020-2031) & (Tons)
- 7.1.2 Global Neurodegenerative Drugs Sales Market Share by Application (2020-2031)
- 7.2 Global Neurodegenerative Drugs Revenue by Application (2020-2031)
- 7.2.1 Global Neurodegenerative Drugs Sales by Application (2020-2031) & (US$ Million)
- 7.2.2 Global Neurodegenerative Drugs Revenue Market Share by Application (2020-2031)
- 7.3 Global Neurodegenerative Drugs Price by Application (2020-2031)
- 8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Neurodegenerative Drugs Value Chain Analysis
- 8.1.1 Neurodegenerative Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Neurodegenerative Drugs Production Mode & Process
- 8.2 Neurodegenerative Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Neurodegenerative Drugs Distributors
- 8.2.3 Neurodegenerative Drugs Customers
- 9 Global Neurodegenerative Drugs Analyzing Market Dynamics
- 9.1 Neurodegenerative Drugs Industry Trends
- 9.2 Neurodegenerative Drugs Industry Drivers
- 9.3 Neurodegenerative Drugs Industry Opportunities and Challenges
- 9.4 Neurodegenerative Drugs Industry Restraints
- 10 Report Conclusion
- 11 Disclaimer
- List of Tables
- Table 1. Secondary Sources
- Table 2. Primary Sources
- Table 3. Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
- Table 4. Market Value Comparison by Application (2020 VS 2024 VS 2031) & (US$ Million)
- Table 5. Global Neurodegenerative Drugs Volume and Revenue Market Size and CAGR of Manufacturers (2020 Versus 2024)
- Table 6. Global Neurodegenerative Drugs Sales (Tons) of Manufacturers (2020-2025)
- Table 7. Global Neurodegenerative Drugs Sales Market Share by Manufacturers (2020-2025)
- Table 8. Global Neurodegenerative Drugs Revenue of Manufacturers (2020-2025)
- Table 9. Global Neurodegenerative Drugs Revenue Share by Manufacturers (2020-2025)
- Table 10. Global Market Neurodegenerative Drugs Average Price (US$/Ton) of Manufacturers (2020-2025)
- Table 11. Global Neurodegenerative Drugs Industry Ranking, 2023 VS 2024 VS 2025
- Table 12. Global Manufacturers of Neurodegenerative Drugs, Manufacturing Sites & Headquarters
- Table 13. Global Manufacturers of Neurodegenerative Drugs, Product Type & Application
- Table 14. Global Neurodegenerative Drugs Manufacturers Established Date
- Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
- Table 16. Global Neurodegenerative Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2024)
- Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans)
- Table 18. TEVA Company Information
- Table 19. TEVA Business Overview
- Table 20. TEVA Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
- Table 21. TEVA Neurodegenerative Drugs Product Portfolio
- Table 22. TEVA Recent Developments
- Table 23. Sanofi Company Information
- Table 24. Sanofi Business Overview
- Table 25. Sanofi Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
- Table 26. Sanofi Neurodegenerative Drugs Product Portfolio
- Table 27. Sanofi Recent Developments
- Table 28. Novartis Company Information
- Table 29. Novartis Business Overview
- Table 30. Novartis Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
- Table 31. Novartis Neurodegenerative Drugs Product Portfolio
- Table 32. Novartis Recent Developments
- Table 33. Luye Pharma Company Information
- Table 34. Luye Pharma Business Overview
- Table 35. Luye Pharma Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
- Table 36. Luye Pharma Neurodegenerative Drugs Product Portfolio
- Table 37. Luye Pharma Recent Developments
- Table 38. Livzon Pharmaceutical Company Information
- Table 39. Livzon Pharmaceutical Business Overview
- Table 40. Livzon Pharmaceutical Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
- Table 41. Livzon Pharmaceutical Neurodegenerative Drugs Product Portfolio
- Table 42. Livzon Pharmaceutical Recent Developments
- Table 43. Kanghong Pharmaceutical Company Information
- Table 44. Kanghong Pharmaceutical Business Overview
- Table 45. Kanghong Pharmaceutical Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
- Table 46. Kanghong Pharmaceutical Neurodegenerative Drugs Product Portfolio
- Table 47. Kanghong Pharmaceutical Recent Developments
- Table 48. Jingxin Pharmaceutical Company Information
- Table 49. Jingxin Pharmaceutical Business Overview
- Table 50. Jingxin Pharmaceutical Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
- Table 51. Jingxin Pharmaceutical Neurodegenerative Drugs Product Portfolio
- Table 52. Jingxin Pharmaceutical Recent Developments
- Table 53. Pfizer Company Information
- Table 54. Pfizer Business Overview
- Table 55. Pfizer Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
- Table 56. Pfizer Neurodegenerative Drugs Product Portfolio
- Table 57. Pfizer Recent Developments
- Table 58. Huahai Pharmaceutical Company Information
- Table 59. Huahai Pharmaceutical Business Overview
- Table 60. Huahai Pharmaceutical Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
- Table 61. Huahai Pharmaceutical Neurodegenerative Drugs Product Portfolio
- Table 62. Huahai Pharmaceutical Recent Developments
- Table 63. Hisun Pharmaceutical Company Information
- Table 64. Hisun Pharmaceutical Business Overview
- Table 65. Hisun Pharmaceutical Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
- Table 66. Hisun Pharmaceutical Neurodegenerative Drugs Product Portfolio
- Table 67. Hisun Pharmaceutical Recent Developments
- Table 68. Haisco Pharmaceutical Company Information
- Table 69. Haisco Pharmaceutical Business Overview
- Table 70. Haisco Pharmaceutical Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
- Table 71. Haisco Pharmaceutical Neurodegenerative Drugs Product Portfolio
- Table 72. Haisco Pharmaceutical Recent Developments
- Table 73. GlaxoSmithKline Company Information
- Table 74. GlaxoSmithKline Business Overview
- Table 75. GlaxoSmithKline Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
- Table 76. GlaxoSmithKline Neurodegenerative Drugs Product Portfolio
- Table 77. GlaxoSmithKline Recent Developments
- Table 78. Ark Pharmaceutical Company Information
- Table 79. Ark Pharmaceutical Business Overview
- Table 80. Ark Pharmaceutical Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
- Table 81. Ark Pharmaceutical Neurodegenerative Drugs Product Portfolio
- Table 82. Ark Pharmaceutical Recent Developments
- Table 83. Dongcheng Biochemicals Company Information
- Table 84. Dongcheng Biochemicals Business Overview
- Table 85. Dongcheng Biochemicals Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
- Table 86. Dongcheng Biochemicals Neurodegenerative Drugs Product Portfolio
- Table 87. Dongcheng Biochemicals Recent Developments
- Table 88. BORA PHARMACEUTICALS Company Information
- Table 89. BORA PHARMACEUTICALS Business Overview
- Table 90. BORA PHARMACEUTICALS Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
- Table 91. BORA PHARMACEUTICALS Neurodegenerative Drugs Product Portfolio
- Table 92. BORA PHARMACEUTICALS Recent Developments
- Table 93. UCB Company Information
- Table 94. UCB Business Overview
- Table 95. UCB Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
- Table 96. UCB Neurodegenerative Drugs Product Portfolio
- Table 97. UCB Recent Developments
- Table 98. Merck Serono Company Information
- Table 99. Merck Serono Business Overview
- Table 100. Merck Serono Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
- Table 101. Merck Serono Neurodegenerative Drugs Product Portfolio
- Table 102. Merck Serono Recent Developments
- Table 103. Boehringer Ingelheim Company Information
- Table 104. Boehringer Ingelheim Business Overview
- Table 105. Boehringer Ingelheim Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
- Table 106. Boehringer Ingelheim Neurodegenerative Drugs Product Portfolio
- Table 107. Boehringer Ingelheim Recent Developments
- Table 108. Biogen Idec Company Information
- Table 109. Biogen Idec Business Overview
- Table 110. Biogen Idec Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
- Table 111. Biogen Idec Neurodegenerative Drugs Product Portfolio
- Table 112. Biogen Idec Recent Developments
- Table 113. Global Neurodegenerative Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
- Table 114. Global Neurodegenerative Drugs Sales by Region (2020-2025) & (Tons)
- Table 115. Global Neurodegenerative Drugs Sales Market Share by Region (2020-2025)
- Table 116. Global Neurodegenerative Drugs Sales by Region (2026-2031) & (Tons)
- Table 117. Global Neurodegenerative Drugs Sales Market Share by Region (2026-2031)
- Table 118. Global Neurodegenerative Drugs Revenue by Region (2020-2025) & (US$ Million)
- Table 119. Global Neurodegenerative Drugs Revenue Market Share by Region (2020-2025)
- Table 120. Global Neurodegenerative Drugs Revenue by Region (2026-2031) & (US$ Million)
- Table 121. Global Neurodegenerative Drugs Revenue Market Share by Region (2026-2031)
- Table 122. North America Neurodegenerative Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 123. North America Neurodegenerative Drugs Sales by Country (2020-2025) & (Tons)
- Table 124. North America Neurodegenerative Drugs Sales by Country (2026-2031) & (Tons)
- Table 125. North America Neurodegenerative Drugs Revenue by Country (2020-2025) & (US$ Million)
- Table 126. North America Neurodegenerative Drugs Revenue by Country (2026-2031) & (US$ Million)
- Table 127. Europe Neurodegenerative Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 128. Europe Neurodegenerative Drugs Sales by Country (2020-2025) & (Tons)
- Table 129. Europe Neurodegenerative Drugs Sales by Country (2026-2031) & (Tons)
- Table 130. Europe Neurodegenerative Drugs Revenue by Country (2020-2025) & (US$ Million)
- Table 131. Europe Neurodegenerative Drugs Revenue by Country (2026-2031) & (US$ Million)
- Table 132. Asia Pacific Neurodegenerative Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 133. Asia Pacific Neurodegenerative Drugs Sales by Country (2020-2025) & (Tons)
- Table 134. Asia Pacific Neurodegenerative Drugs Sales by Country (2026-2031) & (Tons)
- Table 135. Asia Pacific Neurodegenerative Drugs Revenue by Country (2020-2025) & (US$ Million)
- Table 136. Asia Pacific Neurodegenerative Drugs Revenue by Country (2026-2031) & (US$ Million)
- Table 137. South America Neurodegenerative Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 138. South America Neurodegenerative Drugs Sales by Country (2020-2025) & (Tons)
- Table 139. South America Neurodegenerative Drugs Sales by Country (2026-2031) & (Tons)
- Table 140. South America Neurodegenerative Drugs Revenue by Country (2020-2025) & (US$ Million)
- Table 141. South America Neurodegenerative Drugs Revenue by Country (2026-2031) & (US$ Million)
- Table 142. Middle East and Africa Neurodegenerative Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 143. Middle East and Africa Neurodegenerative Drugs Sales by Country (2020-2025) & (Tons)
- Table 144. Middle East and Africa Neurodegenerative Drugs Sales by Country (2026-2031) & (Tons)
- Table 145. Middle East and Africa Neurodegenerative Drugs Revenue by Country (2020-2025) & (US$ Million)
- Table 146. Middle East and Africa Neurodegenerative Drugs Revenue by Country (2026-2031) & (US$ Million)
- Table 147. Global Neurodegenerative Drugs Sales by Type (2020-2025) & (Tons)
- Table 148. Global Neurodegenerative Drugs Sales by Type (2026-2031) & (Tons)
- Table 149. Global Neurodegenerative Drugs Sales Market Share by Type (2020-2025)
- Table 150. Global Neurodegenerative Drugs Sales Market Share by Type (2026-2031)
- Table 151. Global Neurodegenerative Drugs Revenue by Type (2020-2025) & (US$ Million)
- Table 152. Global Neurodegenerative Drugs Revenue by Type (2026-2031) & (US$ Million)
- Table 153. Global Neurodegenerative Drugs Revenue Market Share by Type (2020-2025)
- Table 154. Global Neurodegenerative Drugs Revenue Market Share by Type (2026-2031)
- Table 155. Global Neurodegenerative Drugs Price by Type (2020-2025) & (US$/Ton)
- Table 156. Global Neurodegenerative Drugs Price by Type (2026-2031) & (US$/Ton)
- Table 157. Global Neurodegenerative Drugs Sales by Application (2020-2025) & (Tons)
- Table 158. Global Neurodegenerative Drugs Sales by Application (2026-2031) & (Tons)
- Table 159. Global Neurodegenerative Drugs Sales Market Share by Application (2020-2025)
- Table 160. Global Neurodegenerative Drugs Sales Market Share by Application (2026-2031)
- Table 161. Global Neurodegenerative Drugs Revenue by Application (2020-2025) & (US$ Million)
- Table 162. Global Neurodegenerative Drugs Revenue by Application (2026-2031) & (US$ Million)
- Table 163. Global Neurodegenerative Drugs Revenue Market Share by Application (2020-2025)
- Table 164. Global Neurodegenerative Drugs Revenue Market Share by Application (2026-2031)
- Table 165. Global Neurodegenerative Drugs Price by Application (2020-2025) & (US$/Ton)
- Table 166. Global Neurodegenerative Drugs Price by Application (2026-2031) & (US$/Ton)
- Table 167. Key Raw Materials
- Table 168. Raw Materials Key Suppliers
- Table 169. Neurodegenerative Drugs Distributors List
- Table 170. Neurodegenerative Drugs Customers List
- Table 171. Neurodegenerative Drugs Industry Trends
- Table 172. Neurodegenerative Drugs Industry Drivers
- Table 173. Neurodegenerative Drugs Industry Restraints
- Table 174. Authors List of This Report
- List of Figures
- Figure 1. Research Methodology
- Figure 2. Research Process
- Figure 3. Key Executives Interviewed
- Figure 4. Neurodegenerative Drugs Product Image
- Figure 5. Global Neurodegenerative Drugs Revenue (US$ Million), 2020 VS 2024 VS 2031
- Figure 6. Global Neurodegenerative Drugs Market Size (2020-2031) & (US$ Million)
- Figure 7. Global Neurodegenerative Drugs Sales (2020-2031) & (Tons)
- Figure 8. Global Neurodegenerative Drugs Average Price (US$/Ton) & (2020-2031)
- Figure 9. NMDA Product Image
- Figure 10. SSRIs Product Image
- Figure 11. Dopamine Inhibitors Product Image
- Figure 12. Parkinson’s Disease Product Image
- Figure 13. Amyotrophic Lateral Sclerosis Product Image
- Figure 14. Huntington Disease Product Image
- Figure 15. Alzheimer’s Disease Product Image
- Figure 16. Global Neurodegenerative Drugs Revenue Share by Manufacturers in 2024
- Figure 17. Global Manufacturers of Neurodegenerative Drugs, Manufacturing Sites & Headquarters
- Figure 18. Global Top 5 and 10 Neurodegenerative Drugs Players Market Share by Revenue in 2024
- Figure 19. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
- Figure 20. Global Neurodegenerative Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
- Figure 21. Global Neurodegenerative Drugs Sales by Region in 2024
- Figure 22. Global Neurodegenerative Drugs Revenue by Region in 2024
- Figure 23. North America Neurodegenerative Drugs Market Size by Country in 2024
- Figure 24. North America Neurodegenerative Drugs Sales Market Share by Country (2020-2031)
- Figure 25. North America Neurodegenerative Drugs Revenue Market Share by Country (2020-2031)
- Figure 26. United States Neurodegenerative Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 27. Canada Neurodegenerative Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 28. Europe Neurodegenerative Drugs Market Size by Country in 2024
- Figure 29. Europe Neurodegenerative Drugs Sales Market Share by Country (2020-2031)
- Figure 30. Europe Neurodegenerative Drugs Revenue Market Share by Country (2020-2031)
- Figure 31. Germany Neurodegenerative Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 32. France Neurodegenerative Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 33. U.K. Neurodegenerative Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 34. Italy Neurodegenerative Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 35. Netherlands Neurodegenerative Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 36. Nordic Countries Neurodegenerative Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 37. Asia Pacific Neurodegenerative Drugs Market Size by Country in 2024
- Figure 38. Asia Pacific Neurodegenerative Drugs Sales Market Share by Country (2020-2031)
- Figure 39. Asia Pacific Neurodegenerative Drugs Revenue Market Share by Country (2020-2031)
- Figure 40. China Neurodegenerative Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 41. Japan Neurodegenerative Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 42. South Korea Neurodegenerative Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 43. India Neurodegenerative Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 44. Australia Neurodegenerative Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 45. China Taiwan Neurodegenerative Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 46. Southeast Asia Neurodegenerative Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 47. Southeast Asia Neurodegenerative Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 48. South America Neurodegenerative Drugs Market Size by Country in 2024
- Figure 49. South America Neurodegenerative Drugs Sales Market Share by Country (2020-2031)
- Figure 50. South America Neurodegenerative Drugs Revenue Market Share by Country (2020-2031)
- Figure 51. Mexico Neurodegenerative Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 52. Brazil Neurodegenerative Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 53. Argentina Neurodegenerative Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 54. Colombia Neurodegenerative Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 55. Middle East and Africa Neurodegenerative Drugs Market Size by Country in 2024
- Figure 56. Middle East and Africa Neurodegenerative Drugs Sales Market Share by Country (2020-2031)
- Figure 57. Middle
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.



